Vaxcyte Inc [PCVX] stock is trading at $46.97, down -1.43%. An important factor to consider is whether the stock is rising or falling in short-term value. The PCVX shares have gain 7.46% over the last week, with a monthly amount drifted -6.51%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vaxcyte Inc [NASDAQ: PCVX] stock has seen the most recent analyst activity on September 12, 2025, when Goldman initiated its Neutral rating and assigned the stock a price target of $38. On December 20, 2024, Goldman initiated with a Buy rating and assigned a price target of $135 on the stock. Mizuho started tracking the stock assigning a Buy rating and suggested a price target of $69 on December 07, 2023. TD Cowen initiated its recommendation with an Outperform. Needham reiterated a Buy rating for this stock on January 03, 2023, and upped its price target to $58. In a note dated December 15, 2022, Guggenheim initiated a Buy rating and provided a target price of $66 on this stock.
Vaxcyte Inc [PCVX] stock has fluctuated between $27.66 and $93.77 over the past year. Currently, Wall Street analysts expect the stock to reach $77 within the next 12 months. Vaxcyte Inc [NASDAQ: PCVX] shares were valued at $46.97 at the most recent close of the market. An investor can expect a potential return of 63.93% based on the average PCVX price forecast.
Analyzing the PCVX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.21 and Total Capital is -0.27. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 46.48 points at the first support level, and at 45.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 47.56, and for the 2nd resistance point, it is at 48.15.
Ratios To Look Out For
For context, Vaxcyte Inc’s Current Ratio is 8.83. On the other hand, the Quick Ratio is 8.83, and the Cash Ratio is 1.41.
Transactions by insiders
Recent insider trading involved ELVIA COWAN, Officer, that happened on Dec 23 ’25 when 11623.0 shares were purchased. SVP, GEN COUNSEL & CORP SEC, Eydelman Mikhail completed a deal on Mar 05 ’25 to sell 5000.0 shares. Meanwhile, Officer Eydelman Mikhail bought 5000.0 shares on Mar 05 ’25.
